Charcot-Marie-Tooth disease type 2P
shahr-koh mah-ree tooth
Also known as: CMT2P, LRSAM1-related CMT2P
At a Glance
What is Charcot-Marie-Tooth disease type 2P?
Charcot-Marie-Tooth disease type 2P is a rare genetic disorder that affects the peripheral nervous system. It is caused by mutations in the LRSAM1 gene, which leads to nerve damage over time. The condition typically begins in early adulthood with symptoms like muscle weakness and atrophy, particularly in the feet and hands. As the disease progresses, individuals may experience difficulty walking, balance problems, and loss of sensation. Early symptoms often include foot drop and difficulty with fine motor skills, while later stages can lead to more severe mobility issues. Early diagnosis is crucial for managing symptoms and improving quality of life. The condition can have a significant impact on family life, as it may require lifestyle adjustments and caregiving. Prognosis varies, but many individuals maintain a normal life expectancy with proper management. Daily life for those affected often involves physical therapy and adaptive devices to assist with mobility. Emotional support and counseling can also be beneficial for coping with the challenges of the disease. While there is no cure, ongoing research aims to find more effective treatments. Support groups and resources are available to help families navigate the complexities of living with CMT2P.
Medical Definition
Charcot-Marie-Tooth disease type 2P is a hereditary neuropathy characterized by axonal degeneration due to mutations in the LRSAM1 gene. Pathologically, it involves the degeneration of peripheral nerves, leading to muscle weakness and sensory loss. Histological findings often show axonal loss and demyelination in nerve biopsies. It is classified under the broader category of Charcot-Marie-Tooth disease type 2, which is primarily axonal in nature. Epidemiologically, CMT2P is considered a rare disorder with autosomal dominant inheritance. The disease course is progressive, with symptoms worsening over time, but it typically does not affect life expectancy.
Charcot-Marie-Tooth disease type 2P Symptoms
Symptoms vary in severity between individuals. Early diagnosis and management can significantly improve outcomes.
Very Common
Muscle weakness in Charcot-Marie-Tooth disease type 2P typically begins in the lower extremities, manifesting as difficulty in walking or climbing stairs. This weakness is due to the degeneration of peripheral nerves, which impairs signal transmission to muscles. Over time, the weakness can progress to the upper limbs, leading to difficulties in performing tasks requiring fine motor skills. Daily life is affected as patients may require assistive devices for mobility, and physical therapy can help maintain muscle strength and function.
Sensory loss often presents as a reduced ability to feel pain, temperature, or touch, primarily in the feet and hands. This occurs because of damage to sensory nerves, which disrupts the normal transmission of sensory information to the brain. The progression of sensory loss can lead to injuries due to the inability to perceive harmful stimuli. Patients may need to take precautions to avoid injury and may benefit from occupational therapy to adapt to sensory deficits.
Foot deformities, such as high arches or hammer toes, are common in individuals with Charcot-Marie-Tooth disease type 2P. These deformities result from muscle imbalances caused by nerve degeneration. Over time, these structural changes can lead to pain and difficulty in finding suitable footwear. Orthopedic interventions, such as custom orthotics or surgery, may be necessary to alleviate discomfort and improve mobility.
Common
Gait abnormalities manifest as an unsteady or awkward walking pattern, often described as a 'steppage' gait. This is due to muscle weakness and loss of proprioception, which affects balance and coordination. As the condition progresses, these gait issues can lead to increased fatigue and risk of falls. Physical therapy and assistive devices like braces can help improve gait and reduce fall risk.
Hand weakness in Charcot-Marie-Tooth disease type 2P can lead to difficulties with gripping and manipulating objects. This weakness is caused by the degeneration of motor nerves supplying the hand muscles. Over time, hand weakness can interfere with daily activities such as writing or buttoning clothes. Occupational therapy and adaptive devices can assist in maintaining hand function and independence.
Muscle atrophy is characterized by the wasting away of muscle tissue, particularly in the lower legs and hands. This occurs due to the lack of nerve stimulation and subsequent disuse of affected muscles. As atrophy progresses, it can lead to significant functional impairment and cosmetic concerns. Regular exercise and physical therapy can help slow the progression of atrophy and maintain muscle tone.
Less Common
Tremors in Charcot-Marie-Tooth disease type 2P may present as involuntary shaking, primarily affecting the hands. These tremors are thought to be related to nerve damage and its impact on muscle control. While not progressive, tremors can be exacerbated by stress or fatigue, impacting tasks that require steady hands. Medications and lifestyle modifications can help manage tremors and improve quality of life.
Pain in Charcot-Marie-Tooth disease type 2P can be neuropathic, presenting as burning or shooting sensations, particularly in the extremities. This pain results from nerve damage and can vary in intensity and duration. Chronic pain can significantly affect daily life, leading to sleep disturbances and reduced physical activity. Pain management strategies, including medication and physical therapy, can help alleviate symptoms and improve comfort.
What Causes Charcot-Marie-Tooth disease type 2P?
Charcot-Marie-Tooth disease type 2P is caused by mutations in the LRSAM1 gene, located on chromosome 9q33.3. The LRSAM1 gene encodes an E3 ubiquitin ligase, which is involved in tagging proteins for degradation via the ubiquitin-proteasome system. Mutations such as C698R in the LRSAM1 gene disrupt the protein's ability to bind to its substrates, impairing its ubiquitin ligase activity. This disruption leads to the accumulation of proteins that would normally be degraded, affecting cellular homeostasis. The impaired degradation of proteins causes dysfunction in organelles like the endoplasmic reticulum and Golgi apparatus, leading to defective protein trafficking. Neighboring cells and tissues experience stress due to the buildup of misfolded proteins, triggering cellular apoptosis. Neuroinflammation is exacerbated as immune cells respond to the increased presence of cellular debris and apoptotic cells. This inflammatory response contributes to the degeneration of white matter and peripheral nerves, characteristic of CMT2P. The pattern of symptoms, such as muscle weakness and sensory loss, arises from the specific vulnerability of peripheral nerves to these molecular disruptions. Variability in disease severity among patients can be attributed to differences in the type and location of LRSAM1 mutations, as well as genetic and environmental modifiers. The presence of parkinsonism in some cases suggests additional involvement of dopaminergic pathways. Early-onset cases often involve more severe mutations that lead to rapid disease progression. In contrast, milder mutations may allow for some residual protein function, resulting in later onset and slower progression. The variability in immune response and neuroinflammation also contributes to the heterogeneity of clinical presentations. Understanding these molecular mechanisms provides insight into potential therapeutic targets for CMT2P.
How is Charcot-Marie-Tooth disease type 2P Diagnosed?
Typical age of diagnosis: Charcot-Marie-Tooth disease type 2P is typically diagnosed in early adulthood, often when patients present with progressive muscle weakness and sensory loss. Diagnosis may occur earlier if there is a known family history of the disease, prompting earlier investigation. The condition is characterized by a slow progression, which can delay diagnosis until symptoms significantly impact daily activities. Genetic counseling and testing are often pursued once clinical suspicion is raised.
Clinicians look for signs of distal muscle weakness, atrophy, and sensory loss, particularly in the lower limbs. A detailed family history is crucial, as Charcot-Marie-Tooth disease type 2P is inherited in an autosomal dominant pattern. Physical examination may reveal foot deformities, such as high arches or hammer toes, and reduced deep tendon reflexes. This step helps to differentiate CMT2P from other neuropathies and directs further genetic testing.
Magnetic Resonance Imaging (MRI) of the peripheral nerves is often used to assess nerve structure and integrity. Imaging may show nerve enlargement or hypertrophy, which supports the diagnosis of a hereditary neuropathy. These findings help confirm the diagnosis by correlating clinical symptoms with structural changes. Imaging also helps exclude other conditions such as compressive neuropathies or inflammatory processes.
Nerve conduction studies and electromyography are ordered to assess the electrical activity of muscles and nerves. These tests typically show reduced nerve conduction velocities and axonal degeneration, which are characteristic of CMT2P. Abnormal results guide the clinician towards a hereditary neuropathy rather than an acquired one. Blood tests may be conducted to rule out other causes of neuropathy, such as diabetes or vitamin deficiencies.
Genetic testing focuses on sequencing the LRSAM1 gene, where mutations are known to cause CMT2P. Both missense and loss-of-function mutations can be identified, confirming the diagnosis. The identification of a pathogenic mutation in LRSAM1 confirms the diagnosis and provides information for genetic counseling. This step is crucial for informing family members about their risk and discussing potential implications for future offspring.
Charcot-Marie-Tooth disease type 2P Treatment Options
Gabapentin is an anticonvulsant medication used to manage neuropathic pain associated with CMT2P. It works by modulating neurotransmitter release and reducing neuronal excitability. Clinical studies have shown it can provide significant pain relief, improving quality of life for patients. However, it does not alter disease progression and can cause side effects such as dizziness and fatigue. Its use is typically part of a broader pain management strategy.
Gait training involves exercises and techniques to improve walking ability and balance. The therapeutic goal is to enhance mobility and prevent falls, with sessions typically conducted 2-3 times per week. Progress is measured through improvements in walking speed and balance tests. Long-term benefits include maintained muscle strength and reduced risk of secondary complications. Consistent therapy can significantly enhance daily functioning and independence.
Surgery is indicated for severe foot deformities that impair mobility or cause pain. Procedures may include tendon transfers or osteotomies to correct deformities and improve foot alignment. Expected benefits include improved gait and reduced pain, enhancing overall mobility. Surgical risks include infection, nerve damage, and the need for additional surgeries. Post-operative care involves rehabilitation to maximize surgical outcomes and prevent recurrence.
A multidisciplinary team typically includes neurologists, physiotherapists, occupational therapists, and social workers. Interventions focus on optimizing physical function, managing symptoms, and providing psychosocial support. Strategies include adaptive equipment, counseling, and education on disease management. Family education is crucial for understanding disease progression and care needs. Long-term monitoring ensures timely adjustments to the care plan as the disease progresses.
When to See a Doctor for Charcot-Marie-Tooth disease type 2P
- Sudden loss of mobility — this could indicate rapid disease progression or a secondary complication requiring immediate medical intervention.
- Severe breathing difficulties — may suggest respiratory muscle involvement, which can be life-threatening and requires urgent care.
- Acute confusion or altered mental status — could indicate a neurological emergency or severe systemic involvement.
- Progressive muscle weakness — signifies disease progression; consult a neurologist for management adjustments.
- Persistent numbness or tingling in extremities — may indicate worsening nerve damage; a specialist should evaluate.
- Difficulty with balance or coordination — can lead to falls and injuries; seek advice on physical therapy and safety adaptations.
- Mild fatigue — monitor energy levels and ensure adequate rest; if it worsens, consult a healthcare provider.
- Occasional muscle cramps — track frequency and severity; increase hydration and discuss with a doctor if persistent.
Charcot-Marie-Tooth disease type 2P — Frequently Asked Questions
Is this condition hereditary?
Charcot-Marie-Tooth disease type 2P is inherited in an autosomal dominant pattern, meaning one copy of the altered gene is sufficient to cause the disorder. There is a 50% chance of passing the mutated gene to offspring. De novo mutations can occur, but they are less common. Carriers of the mutation may exhibit symptoms, so genetic counseling is recommended for family planning. Genetic counseling can provide information on inheritance patterns and testing options.
What is the life expectancy for someone with this condition?
Life expectancy for individuals with Charcot-Marie-Tooth disease type 2P is generally normal, though quality of life can be affected by symptom severity. Early onset typically correlates with more significant disability. Mortality is rarely directly caused by the condition but can be influenced by complications such as respiratory issues. Treatment and management strategies can improve quality of life and functional outcomes. Patients should have realistic expectations regarding symptom management and lifestyle adaptations.
How is this condition diagnosed and how long does diagnosis take?
Diagnosis involves clinical evaluation, family history assessment, and genetic testing to confirm LRSAM1 mutations. The time from initial symptoms to diagnosis can vary, often taking months to years due to symptom overlap with other neuropathies. Neurologists and geneticists are typically consulted during the diagnostic process. Delays often occur due to misdiagnosis or lack of awareness of the condition's rarity. Genetic testing provides definitive confirmation of the diagnosis.
Are there any new treatments or clinical trials available?
Research is ongoing, with gene therapy and novel pharmacological approaches being explored. ClinicalTrials.gov is a resource for finding active trials related to Charcot-Marie-Tooth disease type 2P. Patients should discuss trial participation with their healthcare provider to understand potential benefits and risks. New treatments are in development, but timelines for availability can be uncertain. Staying informed about research progress is crucial for accessing new therapies.
How does this condition affect daily life and activities?
Charcot-Marie-Tooth disease type 2P can impact mobility, requiring assistive devices for walking and self-care. Educational accommodations may be necessary for children with the condition. Social and emotional challenges include coping with physical limitations and potential isolation. Family members may experience increased caregiving responsibilities and emotional stress. Supportive therapies and community resources can significantly aid in managing daily life.
Support & Resources
References
Content generated with support from peer-reviewed literature via PubMed.
- 1.Further delineation of LRSAM1-related Charcot-Marie-Tooth type 2P with parkinsonism.
Ducatel P, Verger A, Selton M et al. · Eur J Med Genet · 2025 · PMID: 40721190
- 2.A novel mutation in the LRSAM1 gene in a family with early onset autosomal dominant Charcot-Marie-Tooth type 2P.
Milella G, Amati A, Lastella P et al. · Clin Neurol Neurosurg · 2024 · PMID: 38330802
- 3.C698R mutation in Lrsam1 gene impairs nerve regeneration in a CMT2P mouse model.
Moiseev D, Wazir Z, Liu D et al. · Sci Rep · 2022 · PMID: 35842440
- 4.Deregulation of LRSAM1 expression impairs the levels of TSG101, UBE2N, VPS28, MDM2 and EGFR.
Minaidou A, Nicolaou P, Christodoulou K · PLoS One · 2019 · PMID: 30726272
- 5.LRSAM1 Depletion Affects Neuroblastoma SH-SY5Y Cell Growth and Morphology: The LRSAM1 c.2047-1G>A Loss-of-Function Variant Fails to Rescue The Phenotype.
Minaidou A, Nicolaou P, Christodoulou K · Cell J · 2018 · PMID: 29845787
This content is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.Last reviewed: 2026-04-27